(file photo)
Speed Post News Network
New Delhi : The huge increase in the number of Coronavirus (COVID-19) patients getting cured continues in India reaching 5,34,620 at 8 am on July 12, 2020, an increase of 19,235 during last 24 hours, exceeding the number of active cases by 2,42,362. On the negative side, the death toll has climbed 22,674 with 551 new deaths being reported from different parts of the country including 223 from Maharashtra, 70 from Karnataka, 69 from Tamilnadu, 34 from Delhi, and 26 from West Bengal. The COVID death toll has jumped to 131 in Bihar.
As far Corona patients getting cured goes, 1,36,985 patients have been declared cured in Maharashtra followed by 87,692 in Delhi, 85,915 in Tamilnadu, 22,689 in UP, 20,919 in Telengana, 17,959 in West Bengal, 15,394 in Haryana, 14,716 in Karnataka, 14,393 in Andhra Pradesh, and 10,685 in Bihar.
COVID-19 death toll break-up in India is : Maharashtra (10,116), Delhi (3,334), Gujarat (2,032), Tamilnadu (1,898), UP (913), West Bengal (906), MP (644), Rajasthan (503), Karnataka (613), Telengana (348), Haryana (297), Andhra Pradesh (309), Punjab (195), J&K (169), Bihar (131), Odisha (61), Uttarakhand (46), Assam (35), Kerala (29), Jharkhand (23), Chhattisgarh (17), Puducherry (18), Goa (12), Himachal Pradesh (11), Chandigarh (7), Arunachal Pradesh (2), Meghalaya (2), Tripura (2, and Ladakh (1).
DCGI gives Nod for Restricted Emergency use to Itolizumab for moderate to severe COVID-19 patients : Meanwhile, Itolizumab (rDNA origin), a monoclonal antibody which was already approved for severe chronic plaque psoriasis, has now been granted Restricted Emergency Use authorisation by the Drugs Controller General of India (DCGI) based on clinical trials data. M/s Biocon has been manufacturing and marketing this drug for the treatment of patients with moderate to severe chronic plaque psoriasis under brand name Alzumab.
This indigenous drug has now been repurposed for COVID-19. M/s Biocon has presented the Phase II clinical trial results generated in COVID-19 patients to DCGI. DCGI has decided to grant permission to market the drug under Restricted Emergency Use of the drug for the treatment of Cytokine Release Syndrome (CRS) in moderate to severe Acute Respiratory Distress Syndrome (ARDS) patients due to COVID-19, asccording to a PIB release